Aequus Pharmaceuticals: A Progress Check On The Road To Breakeven [Seeking Alpha]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Seeking Alpha
Aequus Pharmaceuticals: A Progress Check On The Road To Breakeven Aequus Pharmaceuticals OTCQB:AQSZF introductory article Recap of Investment Opportunity The thesis of the investment opportunity in March 2019 has been based on projected revenue growth coming from already marketed products and new in-licensed products. Considering the very small market-cap of around 18Mio CAD, it generates a significant upside opportunity for the share price if events and revenue materialize as projected. Find below a summary of expectations stated in the March 2019 article: Events March-May 2019 Let us summarize the events since the last article of 14th March 2019. It will allow us to compare projection and reality for this period and to revalidate the investment opportunity. Ongoing Revenue Growth: The revenue figures of 507k CAD for Q4/2018 show an impressive revenue growth of +20.7% compared to Q3/2018 (420k CAD). For Q1/2019, however, we see a disappointing 329k CAD of revenue only. The decre
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Cagent Vascular appoints Chairman Brian Walsh to expanded role as Chief Executive Officer [Yahoo! Finance]Yahoo! Finance
- Cagent Vascular appoints Chairman Brian Walsh to expanded role as Chief Executive OfficerBusiness Wire
- CAR T Cell Therapy Market To Reach USD 39.9 Billion By 2032, Says DataHorizzon Research [Yahoo! Finance]Yahoo! Finance
- First-Ever Cost-Effectiveness Analysis of a Factor XI Inhibitor Demonstrates that Abelacimab, if Approved, Could Offer Significant Cost Savings as Compared to a Current Standard of Care Anticoagulant [Yahoo! Finance]Yahoo! Finance
- 2 Magnificent Dividend Stocks to Hold for the Next Decade [Yahoo! Finance]Yahoo! Finance
NVS
Earnings
- 4/23/24 - Beat
NVS
Sec Filings
- 4/23/24 - Form 6-K
- 2/15/24 - Form S-8
- NVS's page on the SEC website